CO2021015793A2 - Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 - Google Patents

Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33

Info

Publication number
CO2021015793A2
CO2021015793A2 CONC2021/0015793A CO2021015793A CO2021015793A2 CO 2021015793 A2 CO2021015793 A2 CO 2021015793A2 CO 2021015793 A CO2021015793 A CO 2021015793A CO 2021015793 A2 CO2021015793 A2 CO 2021015793A2
Authority
CO
Colombia
Prior art keywords
antagonist
methods
treating
administering
preventing asthma
Prior art date
Application number
CONC2021/0015793A
Other languages
English (en)
Spanish (es)
Inventor
Helene Goulaouic
Andreas Jessel
Raolat Abdulai
Ariel Teper
Alex Boddy
Chih-Chi Hu
Deborah Dukovic
Marcella Ruddy
Nikhil Amin
Sivan Harel
Georgios Kalliolias
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of CO2021015793A2 publication Critical patent/CO2021015793A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CONC2021/0015793A 2019-05-01 2021-11-24 Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 CO2021015793A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841481P 2019-05-01 2019-05-01
US201962848248P 2019-05-15 2019-05-15
US201962898900P 2019-09-11 2019-09-11
PCT/US2020/030824 WO2020223541A1 (en) 2019-05-01 2020-04-30 Methods for treating or preventing asthma by administering an il-33 antagonist

Publications (1)

Publication Number Publication Date
CO2021015793A2 true CO2021015793A2 (es) 2021-11-30

Family

ID=70802932

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015793A CO2021015793A2 (es) 2019-05-01 2021-11-24 Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33

Country Status (15)

Country Link
US (1) US20210000949A1 (https=)
EP (1) EP3962515A1 (https=)
JP (2) JP2022530533A (https=)
KR (1) KR20220004708A (https=)
CN (1) CN113766931A (https=)
AU (1) AU2020266593B2 (https=)
BR (1) BR112021021195A2 (https=)
CA (1) CA3138306A1 (https=)
CO (1) CO2021015793A2 (https=)
IL (1) IL287275A (https=)
MA (1) MA55807A (https=)
MX (1) MX2021013427A (https=)
SG (1) SG11202111255YA (https=)
TW (1) TWI894144B (https=)
WO (1) WO2020223541A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
WO2021011614A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
AU2022335719B2 (en) 2021-08-27 2024-11-28 Medimmune Limited Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
MX2024005769A (es) * 2021-11-11 2024-05-24 Regeneron Pharma Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33).
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
JP6306588B2 (ja) * 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
TWI857389B (zh) * 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
ES3052989T3 (en) * 2017-04-13 2026-01-16 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
SG11201909048TA (en) * 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease

Also Published As

Publication number Publication date
MA55807A (fr) 2022-03-09
JP2025122028A (ja) 2025-08-20
AU2020266593B2 (en) 2026-02-12
TWI894144B (zh) 2025-08-21
IL287275A (en) 2021-12-01
EP3962515A1 (en) 2022-03-09
BR112021021195A2 (pt) 2022-03-03
KR20220004708A (ko) 2022-01-11
AU2020266593A1 (en) 2021-11-11
JP2022530533A (ja) 2022-06-29
CA3138306A1 (en) 2020-11-05
CN113766931A (zh) 2021-12-07
MX2021013427A (es) 2022-01-31
US20210000949A1 (en) 2021-01-07
SG11202111255YA (en) 2021-11-29
WO2020223541A1 (en) 2020-11-05
TW202106334A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
JOP20220008A1 (ar) مثبطات parp1
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CR20190311A (es) Composiciones para tratar afecciones inflamatorias
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2022001247A (es) Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
PE20201285A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.